The Trump administration has successfully negotiated deals slashing prescription drug costs in half for millions of Americans struggling with diabetes, obesity, and fertility treatments—delivering real relief.
Story Highlights
- GLP-1 medications for diabetes and weight loss now cost $245 per month through Medicare, roughly half the previous prices
- Fertility drug prices slashed dramatically, with Cetrotide dropping from $316 to $22.50 and average savings exceeding $2,000 per treatment cycle
- TrumpRx.gov platform launched as delivery mechanism for discounted medications, featuring 54 drugs with plans for expansion
- Pharmaceutical giants Eli Lilly, Novo Nordisk, and EMD Serono agreed to Most-Favored-Nation pricing after Trump administration negotiations
Trump Administration Delivers on Drug Pricing Promises
Medicare Director Chris Klomp announced in April 2026 that President Trump’s drug pricing initiatives have produced substantial cost reductions for Americans purchasing GLP-1 medications and fertility drugs.
Patients now pay approximately half what they paid just months earlier, with GLP-1s priced at $245 monthly for Medicare beneficiaries compared to significantly higher costs under the previous administration.
The initiative addresses a critical affordability crisis affecting roughly one-quarter of Americans who cannot afford to fill prescriptions at pharmacy counters. These price cuts represent tangible relief for working families crushed by years of pharmaceutical price gouging that went largely unaddressed.
Fertility Medication Costs Drop Dramatically
The TrumpRx.gov platform launched in February 2026 with dramatic price reductions for fertility medications, offering hope to families pursuing parenthood. Gonal-F now costs $168 per pen, depending on dosage, while Cetrotide plummeted from $316 to $22.50—a reduction exceeding 90 percent.
Ovidrel dropped from $251 to $84, delivering average savings surpassing $2,000 per fertility treatment cycle. These reductions matter significantly given that the average IVF cycle costs $21,600, with medications accounting for $3,000 to $7,000 of that total.
The Trump administration secured these deals through negotiations with EMD Serono, achieving an 84 percent discount on IVF therapies and exempting the manufacturer from Section 232 pharmaceutical tariffs in exchange for increased domestic manufacturing.
Americans paying less as Trump drug pricing push slashes GLP-1, fertility medicine costs, official says https://t.co/9Zt7wC06qp
— FOX Business (@FoxBusiness) April 7, 2026
GLP-1 Drugs Become Accessible for Diabetes and Obesity
Popular GLP-1 medications, including Ozempic, Wegovy, Mounjaro, and Zepbound, now feature substantially lower prices through the TrumpRx platform after years of remaining out of reach for many patients.
Injectable GLP-1s cost $245 per month for Medicare beneficiaries, representing less than half of the Biden administration’s proposed prices.
Direct-to-consumer pricing through TrumpRx offers $350 per month for vials, providing a 30 percent discount from manufacturer-direct pricing of $499. Trulicity for diabetes costs $389 monthly, delivering a $598 discount off the list price.
The administration announced that, pending FDA approval, oral GLP-1 formulations would start at just $150 monthly. Medicare now covers Wegovy and Zepbound for obesity patients with comorbidities, expanding access for Americans struggling with weight-related health conditions.
Platform Scope and Implementation Details
The TrumpRx platform currently lists 54 drugs as of March 2026, with the administration promising continued expansion. Medicare Director Klomp emphasized the initiative’s focus on “delivering on affordability for every American family to be their healthiest self” and solving prescription affordability barriers.
The program demonstrates the pharmaceutical company’s willingness to negotiate pricing when confronted with determined leadership prioritizing American patients over corporate profits.
Major manufacturers, including Eli Lilly and Novo Nordisk, agreed to participate in Most-Favored-Nation pricing arrangements, marking a significant shift from previous resistance to price negotiations.
The American Society for Reproductive Medicine acknowledged that lower drug costs would help patients navigate fertility treatment, though it noted that IVF access requires more than medication discounts alone.
The Trump administration positioned drug pricing as central to its healthcare cost-containment strategy, addressing rising prescription costs that emerged as a top concern for American families. Healthcare costs reclaimed the top spot in American worries after years of inflation and fiscal mismanagement.
These pricing agreements represent concrete achievements in reducing out-of-pocket medical expenses that have crushed household budgets nationwide.
The initiative provides immediate relief for patients who previously faced impossible choices between purchasing necessary medications and meeting other basic family needs.
This approach contrasts sharply with previous failed proposals that prioritized political posturing over practical solutions, delivering real savings to American consumers.
Sources:
What Trump got right and wrong about drug pricing in his State of the Union – ABC News
TrumpRx website launches with discount drug pricing – CBS News
